Description
Description
Zolgensma is approved to treat spinal muscular atrophy (SMA)* in children less than 2 years old. The SMA must be caused by genetic changes in the SMN1 gene. This gene is in nerve cells and helps control muscle function. Zolgensma contains the active ingredient onasemnogene abeparvovec.
Additional information
Additional information
weight | OZ, 1/4 Pound, 1/2 Pound, 1 Pound, 2 Pounds, 3 Pounds, 4 Pounds |
---|
Reviews
There are no reviews yet.